Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status

Journal of Neuro-Oncology

Volumn 44, Issue 2, 1999, Pages 129-136

  Bernsen, H J J A ^a   Rijken, P F J W ^c   Peters, J P W ^c   Bakker, J H ^c   Boerman, R H ^c   Wesseling, P ^c   Van Der Kogel, A J ^b  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c NONE

Author keywords

Antiangiogenesis; Glioma model; Suramine

Indexed keywords

HOE 33342; PIMONIDAZOLE; SURAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FROZEN SECTION; GLIOMA; GROWTH INHIBITION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; OXYGENATION; PERFUSION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH; TUMOR VASCULARIZATION; XENOGRAFT;

EID: 0032804144     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006363215260     Document Type: Article

References (38)

1. Folkman J: Clinical applications of research on angiogenesis. New Engl J Med 333: 1757-1763, 1995
2. Jain RK: Determinants of tumor blood flow: a review. Cancer Res 48: 2641-2658, 1988
3. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465, 1989
4. Auerbach W, Auerbach R: Angiogenesis inhibition: a review. Pharmac Ther 63: 265-311, 1994
5. Fan TD, Jaggar R, Bicknell R: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 16: 57-66, 1995
6. Gagliardi ART, Hadd H, Collins DC: Inhibition of angiogenesis by suramin. Cancer Res 52: 5073-5075, 1992
7. Vignon F, Prebois C, Rochefort H: Inhibition of breast cancer growth by suramin. J Natl Cancer Inst 84: 38-42, 1992
8. Takano S, Gately S, Engelhard H, Tsanaclis AMC, Brem S: Suramin inhibits glioma cell proliferation in vitro and in the brain. J Neuro-Oncol 21: 189-201, 1994
9. Takano S, Gately S, Neville ME, Herblin W, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding to basic fibroblast growth factor, migration, proliferation and induction of urokinase-type plasminogen activator. Cancer Res 54: 2654-2660, 1994
10. Schrell UMH, Gauer S, Kiesewetter F, Bickel A, Hren J, Adams EF, Csoka K, Nygren P, Graf W, Pahlman L, Glimelius B, Larsson R: Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients. Br J Cancer 63: 356-360, 1995
11. Mirza MR, Jakobsen E, Pfeiffer P, Lindebjerg-Clasen B, Bergh J, Rose C: Suramin in non-small cell lung cancer and advanced breast cancer. Acta Oncologica 36: 171-174, 1997
12. Brem SS, Cotran R, Folkman J: Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48: 347-356, 1972
13. Gulledge CJ, Dewhirst MW: Tumor oxygenation: a matter of supply and demand. Anticancer Res 16: 741-750, 1996
14. Potgens AJG, Lubsen NH, van Altena MC, Schoenmakers JCG, Ruiter DJ, de Waal RMW: Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 146: 197-209, 1995
15. Westphal JR, van 't Hullenaar RGM, van der Laak JAWM, Cornelissen IMHA, Schalkwijk LJM, van Muijen GNP, Wesseling P, de Wilde PCM, Ruiter DJ, de Waal RMW: Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br J Cancer 76: 561-570, 1997
16. Rijken PFJW, Bernsen HJJA, van der Kogel AJ: Application of an image analysis system for the quantitation of the tumor perfusion and vascularity in human glioma xenografts. Microvasc Res 50: 141-153, 1995
17. Baghdiguian S, Fantini J: Suramin: a molecule with a broad spectrum of biological and therapeutical properties. Cancer J 10: 31-37, 1997
18. Westphal M, Ackerman E, Hoppe J, Herrmann HD: Receptors for platelet derived growth factor in human glioma lines and influence of suramin on cell proliferation. J Neuro-Oncol 11: 207-213, 1991
19. Pesenti E, Sola F, Mongelli N, Grandi M, Spreafico F: Suramin prevents neovascularization and tumor growth through blocking of fibroblast growth factor activity. Br J Cancer 66: 367-372, 1992
20. Middaugh CR, Mach H, Burke CJ, Volkin DB, Dabora JM, Tsai PK, Bruner MW, Ryan JA, Marfia KE: Nature of the interaction of growth factors with suramin. Biochemistry 31: 9016-9024, 1992
21. Larsen AK: Suramin, an anticancer drug with unique biological effects. Cancer Chemother Pharmacol 32: 96-98, 1993
22. Braddock PS, Hu DE, Fan TPD, Stratford IJ, Harris AL, Bicknell R: A structure-activity analysis of antagonism of growth factor and angiogenesis activity of basic fibroblast growth factor by suramin and related polyanions. Br J Cancer 69: 890-898, 1994
23. Waltenberger J, Mayr U, Frank H, Hombach V: Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action. J Mol Cell Cardiol 28: 1523-1529, 1996
24. Plate KH, Risau W: Angiogenesis in malignant gliomas. Glia 15: 339-347, 1995
25. Coomber BL: Suramin inhibits C6 glioma-induced angiogenesis in vitro. J Cell Biochem 58: 199-207, 1995
26. Olson JJ, Polk DM, Reisner A: The efficacy and distribution of suramin in the treatment of the 9L gliosarcoma. Neurosurgery 34: 297-308, 1994
27. Ramirez LH, Julieron M, Bonnay M, Koscielny S, Zhao Z, Gouyette A, Munck JN: Stimulation of tumor growth in vitro and in vivo by suramin on the VX2 model. Investigational New Drugs 13: 51-53, 1995
28. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS, Ferrara N: Inhibition of VEGF-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993
29. Taki T, Ohnishi T, Arita N, Hiaga S, Saitoh Y, Izumotot S, Mori K, Hayakawa T: Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of angiogenesis. J Neuro-Oncol 19: 251-258, 1994
30. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci 93: 14765-14770, 1996
31. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56: 1615-1620, 1996
32. Bernsen HJJA, Rijken PFJW, Peters H, Bakker H, van der Kogel AJ: The effect of the anti-angiogenic agent AGM-1470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J Neuro-Oncol 38: 51-57, 1998
33. Teicher BA, Dupuis N, Kusomoto T, Robinson MF, Liu F, Menon K, Coleman CN: Antiangiogenic agents can increase tumor oxygenation and responses to radiation therapy. Radiat Oncol Invest 2: 269-276, 1995
34. Kakeji Y, Teicher BA: Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Investigational New Drugs 15: 39-48, 1997
35. Devineni D, Kleinszanto A, Gallo JM: Uptake of tenozolomide in a rat glioma model in presence or absence of the angiogenesis inhibitor TNP-470. Cancer Res 56: 1983-1987, 1996
36. Firsching A, Nickel P, Mor AP, Allolio B: Antiproliferative and angiostatic activity of suramine analogues. Cancer Res 55: 4957-4962, 1995
37. Gagliardi ART, Kassack M, Kreimeyer A, Muller G, Nickel P, Collins DC: Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother Pharmacol 41: 117-124, 1998
38. Kreimeyer A, Muller G, Kassack M, Nickel P, Gagliardi ART: Sulfanilic acid-, Benzenedisulfonic acid-, and Naphthalenetrisulfonic acid analogues. Arch Pharm Pharm Med Chem 331: 97-103, 1998